NEW YORK (GenomeWeb News) – Canadian biomarker test developer GeneNews reported today an uptick in third-quarter revenues to C$400,000 (US$382,000) from C$300,000 in the same quarter last year.

Toronto-based GeneNews attributed the revenue increase to an undisclosed collaborative research agreement; receipts from an Asian biomedical consortium; and sales of its lead product, the ColonSentry biomarker test for prognosing colon cancer risk.

GeneNews slashed its net loss by 64 percent to C$1.4 million from C$3.9 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.